25P-NBOMe

25P-NBOMe (2C-P-NBOMe, NBOMe-2C-P) is a derivative of the phenethylamine 2C-P. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5-HT2A receptor. 25P-NBOMe has been sold as a drug and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe.

Use and effects The dose range of 25P-NBOMe has been given as 0.1 to 1.5mg sublingually, with a typical dose estimate of 0.6mg.

Toxicity and harm potential

Neurotoxic and cardiotoxic actions

Emergency treatment

Interactions

Pharmacology Pharmacodynamics + Target Affinity (Ki, nM) 5-HT1A 1,800 5-HT1B 5-HT1D 5-HT1E 5-HT1F 5-HT2A 0.630–1.1 (Ki)63.0–220 ()42–94% () 5-HT2B 20.0 (Ki)170 ()23% () 5-HT2C 6.0 (Ki)25.1 ()109% () 5-HT3 5-HT4 5-HT5A 5,100 5-HT6 140.8 5-HT7 2,905 α1A 310 α1B, α1D α2A 410 α2B, α2C β1–β3 D1 3,100 D2 870 D3 2,300 D4, D5 H1 1,700 H2–H4 M1–M5 I1 σ1, σ2 240 (Ki) (mouse)55–60 (Ki) (rat)1,300 () (mouse)510 () (rat)>10,000 () (human)40% () (mouse)34% () (rat) 5,200 (Ki)12,000 () () 2,800 (Ki)14,000 () () 4,700 (Ki)82,000 () () Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:

25P-NBOMe is a potent agonist of the serotonin 5-HT2 receptors, including the serotonin 5-HT2A receptor.

History 25P-NBOMe was first described in the scientific literature by 2012.Casale, J. F., & Hays, P. A. (2012). Characterization of eleven 2, 5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) derivatives and differentiation from their 3-and 4-methoxybenzyl analogues—part I. Microgram Journal, 9(2), 84–109. https://www.dea.gov/sites/default/files/pr/microgram-journals/2012/mj9_84-109.pdf

Society and culture Legal status Canada 25P-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.

United Kingdom

25P-NBOMe

Bron en licentie